Balyasny Asset Management LLC Vertex Pharmaceuticals Inc Call Options Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $230,000 - $252,890	-500 Reduced 50.0%	500 $232,000
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $196,405 - $242,765	500 Added 100.0%	1,000 $468,000
Q1 2024 May 13, 2024	SELL	$407.69 - $446.08 $122,307 - $133,824	-300 Reduced 37.5%	500 $209,000
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $274,400 - $328,544	800 New	800 $325,000
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $3.53 Million - $3.94 Million	12,900 Added 330.77%	16,800 $4.86 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $12.2 Million - $15.2 Million	-52,100 Reduced 93.04%	3,900 $1.1 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $69.5 Million - $81.9 Million	-314,000 Reduced 84.86%	56,000 $14.6 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $58.6 Million - $74 Million	331,000 Added 848.72%	370,000 $81.3 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $7.31 Million - $8.62 Million	39,000 New	39,000 $7.86 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $4.05 Million - $4.73 Million	-26,700 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $3.67 Million - $4.15 Million	26,700	26,700 $4 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.